Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
CNY 12.67
(-0.63%)
CNY 12.67
(-0.63%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 220.98 Million CNY | -38.25% |
| 2022 | 387.19 Million CNY | 20.09% |
| 2021 | 322.42 Million CNY | 56.02% |
| 2020 | 206.65 Million CNY | 2.54% |
| 2019 | 201.54 Million CNY | 22.73% |
| 2018 | 164.21 Million CNY | 6.31% |
| 2017 | 154.47 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 50.82 Million CNY | -48.76% |
| 2024 Q3 | 35.65 Million CNY | -27.39% |
| 2024 Q1 | 99.19 Million CNY | 147.82% |
| 2023 Q2 | 44.7 Million CNY | -66.95% |
| 2023 FY | 239.09 Million CNY | -38.25% |
| 2023 Q4 | 40.02 Million CNY | 109.54% |
| 2023 Q3 | 19.1 Million CNY | -57.27% |
| 2023 Q1 | 135.26 Million CNY | 44.15% |
| 2022 Q3 | 28.6 Million CNY | -48.7% |
| 2022 Q2 | 55.77 Million CNY | -73.31% |
| 2022 Q1 | 208.97 Million CNY | 65.49% |
| 2022 FY | 387.19 Million CNY | 20.09% |
| 2022 Q4 | 93.83 Million CNY | 228.01% |
| 2021 FY | 322.42 Million CNY | 56.02% |
| 2021 Q4 | 126.27 Million CNY | 341.06% |
| 2021 Q3 | 28.63 Million CNY | -58.76% |
| 2021 Q2 | 69.41 Million CNY | -29.24% |
| 2021 Q1 | 98.1 Million CNY | 90.31% |
| 2020 FY | 206.65 Million CNY | 2.54% |
| 2020 Q4 | 51.54 Million CNY | 177.63% |
| 2020 Q3 | 18.56 Million CNY | -66.49% |
| 2020 Q2 | 55.4 Million CNY | -31.72% |
| 2020 Q1 | 81.13 Million CNY | 0.0% |
| 2019 FY | 201.54 Million CNY | 22.73% |
| 2018 FY | 164.21 Million CNY | 6.31% |
| 2017 FY | 154.47 Million CNY | 0.0% |